FindTrial
Sign In

LY3410738

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Acute Myeloid Leukemia (AML)Any Solid TumorCholangiocarcinomaChondrosarcomaChronic Myelomonocytic Leukemia (CMML)GliomaHealthyMyelodysplastic Syndrome (MDS)

Phase 1

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Active, not recruitingNCT04521686
Eli Lilly and CompanyAny Solid Tumor, Cholangiocarcinoma, Chondrosarcoma +1
Start: 2020-10-01End: 2027-05-01Target: 200Updated: 2026-07-22
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Active, not recruitingNCT04603001
Eli Lilly and CompanyAcute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS) +1
Start: 2020-11-19End: 2027-05-01Target: 260Updated: 2026-07-22
Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants
TerminatedNCT05205447
Eli Lilly and CompanyHealthy
Start: 2022-01-05End: 2022-04-12Updated: 2022-12-28
A Study of LY3410738 in Healthy Adult Participants
CompletedNCT06181045
Eli Lilly and CompanyHealthy
Start: 2021-02-24End: 2021-08-04Updated: 2023-12-26
A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants
CompletedNCT06181084
Eli Lilly and CompanyHealthy
Start: 2021-10-11End: 2022-04-28Updated: 2023-12-26

Related Papers

Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
2025-12-011 citations
Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025-12-01
Abstract CT098: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced IDH-mutant cholangiocarcinoma and other solid tumors
Cancer Research2023-04-1413 citations
Abstract CT026: A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies
Cancer Research2023-04-142 citations
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
HemaSphere2021-06-0112 citations
A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
Journal of Clinical Oncology2021-01-2024 citations